MergersCorp M&A International

AUGUST 9, 2024

These funds typically invest in publicly traded securities and derivatives, allowing for a wide range of investment tactics that can include long and short positions, derivatives trading, and leveraging. Exiting an investment often requires a sale, merger, or public offering of the target company.

Private Equity 52

Private Equity Equities Funds Investment 52

Intrepid Banker Insights

MARCH 28, 2023

An increase in days sales outstanding (DSO) may be a sign that customers are experiencing challenges, an early indicator of liquidity issues down the line. In addition to watching for inventory buildup, businesses should pay close attention to their accounts receivable collection time.

Capital 52

Capital Advisory Banking Bank 52

Solganick & Co.

APRIL 24, 2024

Private equity buyers have opted to acquire systems integration businesses almost exclusively through their established portfolio companies, or add-on’s. Note : Solganick has advised on the sale of three Snowflake Partners over the last 24 months; and advised on the sale of 4 additional data analytics firms.

Mergers 52

Mergers Mergers and Acquisitions M&A Consulting 52

Cooley M&A

SEPTEMBER 16, 2022

In addition, currently public dual-class companies with transfer provisions that do not contain clear carve outs for the delivery of voting agreements in the M&A context should discuss with their advisers the possibility of adopting “clear day” amendments to their charters to include these carve outs. Vote-down termination fee (i.e.,

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

approved prescription cannabidiol medicine to its portfolio. For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses. driven assets. closing friction.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

Similarly, we expect sponsors to actively pursue carve out opportunities – like Francisco Partners’ carve out acquisition of the data and analytics assets from IBM’s Watson Health business – in 2023 as tech giants streamline their portfolios to focus on their core businesses.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Focus Investment Banking

DECEMBER 20, 2024

While questions around the ultimate buyers of these organizations have been building, the sale of RCA, the largest retina practice portfolio in the U.S., This sale allows Cencora to capture additional profitability through the delivery phase at retina practices (and gain or retain them as customers).

Private Equity 52

Private Equity Healthcare Equities Sale 52

Focus Investment Banking

FEBRUARY 11, 2025

Overcoming Marketplace Uncertainty Rising interest rates introduced a difficult environment for private equity recapitalizations (where private equity groups sell a portfolio company to another buyer), so few of the older PE-backed ophthalmology organizations traded hands over the last few years.

Private Equity 52

Private Equity Healthcare Equities Medical 52

Cooley M&A

JANUARY 22, 2025

By 2030, more than 190 commercial drugs will lose patent exclusivity , putting at risk $236 billion in Big Pharma sales. The sale of Poseida Therapeutics, a cell and gene therapy-focused company, for up to $1.5 billion sale of Carmot Therapeutics, a promising Swiss GLP-1 drug developer, further underscores the sectors vitality.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64